A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors

Conditions

Phase I

Phase IB

Volunteers
Health Professionals

What is the purpose of this trial?

A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors

Find out more about who can participate in this trial

Trial with
Sotio
Start Date
01/21/2020
End Date
03/21/2022

For more information about this study, contact:

Ingrid Palma

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Patricia LoRusso, DO
Professor of Medicine (Medical Oncology); Professor of Medicine; Associate Cancer Center Director of Experimental Therapeutics, Yale Cancer Center

Sub-Investigators

Last Updated
07/07/2020
Study HIC
#2000025523

A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information